Nucala (mepolizumab), First Drug to Treat Group of Rare Blood Disorders in Nearly 14 Years
27 Settembre 2020
The Food and Drug Administration has approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months
